Proteomic Profile Regulated by the Anticancer Peptide CIGB-300 in Non-Small Cell Lung Cancer (NSCLC) Cells
详细信息 查看全文
- 作者：Arielis Rodrguez-Ulloa ; Yassel Ramos ; Jeovanis Gil ; Yasser Perera ; Lila Castellanos-Serra ; Yairet Garca ; Lzaro Betancourt ; Vladimir Besada ; Luis J. Gonzlez ; Jorge Fernndez-de-Cossio ; Aniel Sanchez ; Jo
- 刊名：Journal of Proteome Research
- 出版年：2010
- 出版时间：October 1, 2010
- 年：2010
- 卷：9
- 期：10
- 页码：5473-5483
- 全文大小：425K
- 年卷期：v.9,no.10(October 1, 2010)
- ISSN：1535-3907
文摘
CIGB-300 is a proapoptotic peptide-based drug that abrogates the CK2-mediated phosphorylation. This peptide has antineoplastic effect on lung cancer cells in vitro and in vivo. To understand the mechanisms involved on such anticancer activity, the NCI-H125 cell line proteomic profile after short-term incubation (45 min) with CIGB-300 was investigated. As determined by 2-DE or 2D-LC−MS/MS, 137 proteins changed their abundances more than 2-fold in response to the CIGB-300 treatment. The expression levels of proteins related to ribosome biogenesis, metastasis, cell survival and proliferation, apoptosis, and drug resistance were significantly modulated by the presence of CIGB-300. The protein translation process was the most affected (23% of the identified proteins). From the proteome analysis of the NCI-H125 cell line, novel potentialities for CIGB-300 as anticancer agent were evidenced.